We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AbCellera Biologics Inc | NASDAQ:ABCL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.08 | -1.95% | 4.03 | 4.03 | 4.04 | 4.28 | 4.02 | 4.12 | 1,185,587 | 18:58:11 |
By Kimberly Chin
AbCellera Biologics Inc. reported positive results for an advanced trial of its Covid-19 combination treatment, as the company seeks to expand its antibody therapy globally.
The Vancouver, Canada-based biotechnology firm, alongside its partner Eli Lilly & Co., said their bamlanivimab (LY-CoV555) treatment in combination with etesevimab reduced hospitalizations and deaths in Covid-19 positive patients at high risk by 87% compared with a placebo, the company said.
This was the second Phase 3 trial of the combination treatment with positive results, AbCellera said.
The study's results support the use of its combination antibody therapy, adding to its safety and efficacy profile, the company said. AbCellera's Covid-19 treatment was granted emergency-use authorization by the U.S. Food and Drug Administration and given a positive scientific opinion by the European Medicine Agency's committee that evaluates such treatments for human use.
AbCellera's shares rose 5.3% to $32.28 Wednesday.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
March 10, 2021 12:17 ET (17:17 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year AbCellera Biologics Chart |
1 Month AbCellera Biologics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions